Bioactivity:

CPX-351 is a Liposomal-encapsulated combination of daunorubicin and cytarabine for the treatment of newly diagnosed tAML or AML with myelodysplasia-related changes (AML-MRCs).

CAS nr:

1256639-86-7

Purity:

98%

Molecular Weight:

770,75

SMILES:

O=C1C2=C(O)C([C@@H](O[C@@H]3O[C@@H](C)[C@@H](O)[C@@H](N)C3)C[C@](O)(C(C)=O)C4)=C4C(O)=C2C(C5=CC=CC(OC)=C51)=O.O=C6N=C(N)C=CN6[C@@H]7O[C@H](CO)[C@@H](O)[C@@H]7O

Formula:

C36H42N4O15

Pathway:

Target: